Targeted radiation for limited cancer spread vs. standard care
Part of Cancer clinical trials.
This trial tests whether high-precision radiation (SBRT) can improve outcomes for people with up to 5 small, stable metastases from certain cancers, compared to usual palliative care. It is for those whose disease is not growing after current chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have 1 to 5 cancer spots (metastases) that have not spread to many organs, with no more than 3 in any one organ.
- Your cancer must be one of these types: colon, rectal, lung, breast, prostate, or kidney cancer.
- Your overall health is good enough to be up and active most of the day (ECOG score 0-2).
- Your disease is not getting worse on your current chemotherapy.
- You have not had radiation to any of these cancer spots before.
- Your life expectancy is more than 6 months (if you have brain spots, they are favorable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two types of radiation for people whose cancer has spread to a few new spots while on or after treatment. It tests whether a precise, high-dose radiation approach (stereotactic) works better than the usual palliative radiation for controlling these growing spots.
This trial compares two types of highly focused radiation (ablative radiosurgery versus stereotactic radiation in 5 sessions) for people with a small number of metastases in the bone. It aims to find which approach controls these spots with fewer side effects while keeping the treatment “radical,” meaning trying to wipe out the targeted lesions.
This trial tests whether giving immune-supporting cells (lymphocytes) alongside focused radiation (SBRT) can help control limited cancer spread. People with 1 to 5 small tumors that can all be radiated within two weeks may be eligible.
This trial compares giving stereotactic ablative radiotherapy as one larger treatment plan versus several smaller plans for people who have only a few cancer spots (or a few spots that are worsening). It may help control metastatic disease while aiming to protect surrounding healthy organs.
This observational study follows people with rare solid tumors and a limited number of metastases treated with a focused radiation technique (SBRT). Doctors want to see outcomes after using a strong, curative-intent radiation dose to all active spots.
This trial tests a faster way to give radiation to people with a few spots of cancer that have spread. They use a special scan to plan treatment right away, so you may not need a separate planning visit.
Hear when a new Oligometastatic Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.